2021 ESMO临床实践指南:转移性乳腺癌的诊断、分期和治疗

2021-10-13 欧洲肿瘤内科学会 Ann Oncol

2021年10月,欧洲肿瘤内科学会发布了转移性乳腺癌的诊断、分期和治疗指南。文章主要针对转移性乳腺癌的管理提供关键指导建议和流程,内容涵盖了诊断、分期、风险评估、治疗、疾病监测、姑息治疗等。

中文标题:

2021 ESMO临床实践指南:转移性乳腺癌的诊断、分期和治疗

英文标题:

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

发布机构:

欧洲肿瘤内科学会

发布日期:

2021-10-13

简要介绍:

2021年10月,欧洲肿瘤内科学会(ESMO)发布了转移性乳腺癌的诊断、分期和治疗指南。文章主要针对转移性乳腺癌的管理提供关键指导建议和流程,内容涵盖了诊断、分期、风险评估、治疗、疾病监测、姑息治疗等。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 ESMO临床实践指南:转移性乳腺癌的诊断、分期和治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=1ee721c002239044, title=2021 ESMO临床实践指南:转移性乳腺癌的诊断、分期和治疗, enTitle=ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, guiderFrom=Ann Oncol, authorId=0, author=, summary=2021年10月,欧洲肿瘤内科学会发布了转移性乳腺癌的诊断、分期和治疗指南。文章主要针对转移性乳腺癌的管理提供关键指导建议和流程,内容涵盖了诊断、分期、风险评估、治疗、疾病监测、姑息治疗等。, cover=https://img.medsci.cn/20211026/1635259400157_1608702.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology )是1975年成立的非盈利组织,是欧洲领先的专业组织,致力于提高肿瘤内科的专业性,推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Wed Oct 13 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年10月,欧洲肿瘤内科学会(ESMO)发布了转移性乳腺癌的诊断、分期和治疗指南。文章主要针对转移性乳腺癌的管理提供关键指导建议和流程,内容涵盖了诊断、分期、风险评估、治疗、疾病监测、姑息治疗等。</span></p>, tagList=[TagDto(tagId=5047, tagName=转移性乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=5047, guiderKeyword=转移性乳腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=49141, appHits=174, showAppHits=0, pcHits=966, showPcHits=48967, likes=0, shares=10, comments=4, approvalStatus=1, publishedTime=Tue Oct 26 23:11:12 CST 2021, publishedTimeString=2021-10-13, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Tue Oct 26 22:48:41 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 14:46:38 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ESMO临床实践指南:转移性乳腺癌的诊断、分期和治疗.pdf)])
2021 ESMO临床实践指南:转移性乳腺癌的诊断、分期和治疗.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1079012, encodeId=006010e9012a2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d81e2801105, createdName=1020235510, createdTime=Sat Dec 11 10:53:20 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064930, encodeId=8ddd10649300f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Fri Oct 29 10:32:54 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064764, encodeId=62851064e64be, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28132418482, createdName=1238f3a5m35(暂无昵称), createdTime=Thu Oct 28 19:28:25 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064248, encodeId=b83c1064248a9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ba5398350, createdName=柴胡配黄芩, createdTime=Wed Oct 27 04:21:32 CST 2021, time=2021-10-27, status=1, ipAttribution=)]
    2021-12-11 1020235510

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1079012, encodeId=006010e9012a2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d81e2801105, createdName=1020235510, createdTime=Sat Dec 11 10:53:20 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064930, encodeId=8ddd10649300f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Fri Oct 29 10:32:54 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064764, encodeId=62851064e64be, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28132418482, createdName=1238f3a5m35(暂无昵称), createdTime=Thu Oct 28 19:28:25 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064248, encodeId=b83c1064248a9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ba5398350, createdName=柴胡配黄芩, createdTime=Wed Oct 27 04:21:32 CST 2021, time=2021-10-27, status=1, ipAttribution=)]
    2021-10-29 JZ Yang

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1079012, encodeId=006010e9012a2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d81e2801105, createdName=1020235510, createdTime=Sat Dec 11 10:53:20 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064930, encodeId=8ddd10649300f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Fri Oct 29 10:32:54 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064764, encodeId=62851064e64be, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28132418482, createdName=1238f3a5m35(暂无昵称), createdTime=Thu Oct 28 19:28:25 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064248, encodeId=b83c1064248a9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ba5398350, createdName=柴胡配黄芩, createdTime=Wed Oct 27 04:21:32 CST 2021, time=2021-10-27, status=1, ipAttribution=)]
    2021-10-28 1238f3a5m35(暂无昵称)

    值得学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1079012, encodeId=006010e9012a2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d81e2801105, createdName=1020235510, createdTime=Sat Dec 11 10:53:20 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064930, encodeId=8ddd10649300f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Fri Oct 29 10:32:54 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064764, encodeId=62851064e64be, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28132418482, createdName=1238f3a5m35(暂无昵称), createdTime=Thu Oct 28 19:28:25 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064248, encodeId=b83c1064248a9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ba5398350, createdName=柴胡配黄芩, createdTime=Wed Oct 27 04:21:32 CST 2021, time=2021-10-27, status=1, ipAttribution=)]
    2021-10-27 柴胡配黄芩

    学习

    0

拓展阅读

2018 AGO建议:晚期和转移性乳腺癌的诊断和治疗(更新版)

德国妇科肿瘤小组(AGO,German Gynecological Oncology Group) · 2018-07-13

复发/转移性乳腺癌标志物临床应用专家共识(2019年版)

中国抗癌协会(Chinese Anti-cancer Association) · 2019-10-30

2021 AGO建议:局部晚期和转移性乳腺癌的诊断与治疗(更新版)

德国妇科肿瘤小组(AGO,German Gynecological Oncology Group) · 2021-06-20

2022 ASCO 指南更新:转移性乳腺癌全身治疗的生物标志物

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2022-06-27

ASCO指南更新:生物标志物指导转移性乳腺癌的系统性治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2022-06-27